NCT01484561 - A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

February 28, 2013

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

CP-690,550 or Placebo

CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days

DRUG

Placebo

Placebo BID orally, approximately 72 days

Trial Locations (24)

12206

Pfizer Investigational Site, Albany

13125

Pfizer Investigational Site, Berlin

15006

Pfizer Investigational Site, A Coruña

16635

Pfizer Investigational Site, Duncansville

33143

Pfizer Investigational Site, South Miami

41009

Pfizer Investigational Site, Seville

48013

Pfizer Investigational Site, Bilbao

48903

Pfizer Investigational Site, Barakaldo

75231

Pfizer Investigational Site, Dallas

91054

Pfizer Investigational Site, Erlangen

97000

Pfizer Investigational Site, Mérida

97080

Pfizer Investigational Site, Würzburg

98405

Pfizer Investigational Site, Tacoma

115522

Pfizer Investigational Site, Moscow

185019

Pfizer Investigational Site, Petrozavodsk

194291

Pfizer Investigational Site, Saint Petersburg

197341

Pfizer Investigational Site, Saint Petersburg

140 59

Pfizer Investigational Site, Prague

15-354

Pfizer Investigational Site, Bialystok

85-168

Pfizer Investigational Site, Bydgoszcz

01-192

Pfizer Investigational Site, Warsaw

02-256

Pfizer Investigational Site, Warsaw

50-088

Pfizer Investigational Site, Wroclaw

120-752

Pfizer Investigational Site, Seoul